Geode Capital Management LLC Acquires 49,367 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Geode Capital Management LLC boosted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 2.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,343,310 shares of the company’s stock after buying an additional 49,367 shares during the period. Geode Capital Management LLC owned approximately 2.30% of Intellia Therapeutics worth $48,164,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. EverSource Wealth Advisors LLC lifted its holdings in shares of Intellia Therapeutics by 763.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock worth $39,000 after acquiring an additional 1,550 shares during the period. Eastern Bank bought a new position in shares of Intellia Therapeutics during the third quarter valued at $41,000. Values First Advisors Inc. acquired a new position in Intellia Therapeutics in the third quarter valued at about $54,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Intellia Therapeutics by 27.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after acquiring an additional 794 shares in the last quarter. Finally, KBC Group NV lifted its position in Intellia Therapeutics by 37.3% during the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock worth $77,000 after buying an additional 1,020 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Trading Down 0.7 %

Intellia Therapeutics stock opened at $12.10 on Tuesday. Intellia Therapeutics, Inc. has a 1-year low of $11.79 and a 1-year high of $34.87. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -2.22 and a beta of 1.76. The firm has a 50 day simple moving average of $15.44 and a 200 day simple moving average of $20.16.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to analysts’ expectations of $8.28 million. During the same period in the previous year, the business earned ($1.38) EPS. The business’s revenue was down 24.1% on a year-over-year basis. On average, equities research analysts forecast that Intellia Therapeutics, Inc. will post -5.12 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on NTLA shares. Stifel Nicolaus cut their price target on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a research note on Wednesday, September 11th. Wells Fargo & Company cut their target price on shares of Intellia Therapeutics from $80.00 to $70.00 and set an “overweight” rating on the stock in a report on Monday, November 18th. StockNews.com raised Intellia Therapeutics to a “sell” rating in a research report on Friday, November 8th. Robert W. Baird cut their price objective on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $54.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, September 19th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $54.94.

Insider Activity

In related news, CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the transaction, the chief accounting officer now owns 47,012 shares in the company, valued at $893,698.12. The trade was a 4.10 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 3.20% of the company’s stock.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.